51¾«Æ·ÊÓƵ

Tags
  • School of Pharmacy
  • School of Medicine
  • Department of Psychiatry
  • Department of Pharmacy and Therapeutics
  • Department of Medicine
Accolades & Honors

51¾«Æ·ÊÓƵ Professors to Examine COVID-19 Measures’ Impact on Opioid Use Disorder Populations, Providers

The 51¾«Æ·ÊÓƵ, NYU Grossman School of Medicine and the University of Arizona will assess the impact of COVID-19 measures on providers and at-risk opioid use disorder populations in Pennsylvania, New York and Arizona.

Antoine Douaihy, professor of psychiatry and medicine, and Janice Pringle, professor of pharmacy and therapeutics, are leading 51¾«Æ·ÊÓƵ’s efforts.

In 2017, Pennsylvania designated 45 primary care providers, hospitals, community health centers and substance use disorder treatment providers as Centers of Excellence for Opioid Use Disorder. The 51¾«Æ·ÊÓƵ will examine how providers at these whole person, integrated care centers implemented COVID-19-policies related to providing medications for opioid use disorder and telehealth services. The project will look at the impact of temporary COVID-19 policies on opioid use disorder treatment, workforce morale and patient outcomes.

51¾«Æ·ÊÓƵ's researchers received $100,000 as a part of a larger project by the Foundation for Opioid Response Efforts to assess the impact of COVID-19 on opioid use disorder treatment and equity.